`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`APPLE INC.,
`
`Petitioner
`v.
`
`JAWBONE INNOVATIONS, LLC,
`
`Patent Owner
`
`
`
`
`
`
`
`
`
`Case IPR2022-01084
`
`U.S. Patent No. 8,321,213
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PETITIONER’S PRELIMINARY REPLY
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`APPLE-1001
`
`U.S. Patent No. 8,321,213 to Petit et al. (“the ’213 patent”)
`
`APPLE-1002
`
`Excerpts from the Prosecution History of the ’213 patent (“the
`Prosecution History”)
`
`APPLE-1003
`
`Declaration of Dr. Thomas Kenny
`
`APPLE-1004
`
`Curriculum Vitae of Dr. Thomas Kenny
`
`APPLE-1005
`
` U.S. Patent No. 8,194,880 B2 (“Avendano”)
`
`APPLE-1006
`
` U.S. Patent No. 7,464,029 B2 (“Visser”)
`
`APPLE-1007
`
` RESERVED
`
`APPLE-1008
`
` U.S. Patent No. 7,155,019 B2 (“Hou”)
`
`APPLE-1009
`
` Byrne, D, et al, “An international comparison of long-term
`average speech spectra,” 1994 Oct; J. Acoust. Soc. Am.; 96(4):
`2108-2120 (“Byrne”).
`
`APPLE-1010
`
` U.S. Publication No. US 2011/0103626 A1 (“Bisgaard”)
`
`APPLE-1011
`
` U.S. Provisional App. No. 60/816,244 (“the Bisgaard
`Provisional”)
`
`APPLE-1012
`
` U.S. Publication No. US 2002/0198705 A1 (“Burnett”)
`
`APPLE-1013
`
` Berglund, B, et al, “Source and effects of low-frequency noise,”
`1996 May; J. Acoust. Soc. Am; 99(5): 2985-3002 (“Berglund”).
`
`APPLE-1014
`
` Declaration of June Ann Munford
`
`APPLE-1015
`
` Declaration of June Ann Munford - Appendix
`
`
`
`i
`
`
`
`
`
`
`APPLE-1016
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
` Curriculum Vitae of June Ann Munford
`
`APPLE-1017
`
` RESERVED
`
`APPLE-1018
`
` Ryan David, Positive COVID Tests Derail Intel Patent Trial In
`WDTX, LAW360 (Apr. 26, 2022, 1:16PM),
`https://www.law360.com/articles/1487451
`
`APPLE-1019
`
` Dani Kass, Fintiv Fails: PTAB Uses ‘Remarkably Inaccurate’
`Trial Dates, LAW360 (Nov. 2, 2021, 9:09 PM),
`https://www.law360.com/articles/1436071
`
`APPLE-1020
`
` Motion to Transfer (Public Version) – Jawbone Innovations,
`LLC v. Apple Inc., 6:21-cv-00984, D.I. 47 (W.D. Tex. May 6,
`2022)
`
`APPLE-1021
`
` Motion to Transfer (Public Version) – Jawbone Innovations,
`LLC v. Google LLC, 6:21-cv-00985, D.I. 43 (W.D. Tex. Apr.
`29, 2022)
`
`APPLE-1022
`
` Motion to Transfer – Jawbone Innovations, LLC v.
`Amazon.com, Inc., 2:21-cv-00435, D.I. 25
`(E.D. Tex. Mar.
`10, 2022)
`
`APPLE-1023
`
` Complaint – Jawbone Innovations, LLC v. Apple Inc., 6:21-cv-
`00984, D.I. 1 (W.D. Tex. Sep. 23, 2021)
`
`APPLE-1024
`
` Scheduling Order – Jawbone Innovations, LLC v. Apple Inc.,
`6:21-cv-00984, D.I. 23 (W.D. Tex. Jan. 7, 2022)
`
`APPLE-1025
`
` Press Release of U.S. Senator Patrick Leahy of Vermont
`
`APPLE-1026
`
` Legislative Proposal - Restoring the America Invents Act
`
`APPLE-1027
`
` Complaint – Jawbone Innovations, LLC v. Google LLC, 6:21-
`cv-00985, D.I. 1 (W.D. Tex. Sep. 23, 2021)
`
`
`
`
`
`ii
`
`
`
`
`
`
`APPLE-1028
`
`
`
`
`
`
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
` Amended Scheduling Order – Jawbone Innovations, LLC v.
`Apple Inc., 6:21-cv-00984, D.I. 23 (W.D. Tex. Oct. 20, 2022)
`
`iii
`
`
`
`
`
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
`I.
`INTRODUCTION
`Petitioner below addresses the proper application of the Fintiv factors under
`
`the USPTO’s Interim Procedure for Discretionary Denials (“Guidance”), and
`
`demonstrates that denial would be inappropriate.
`
`II.
`
`FINTIV FACTORS 1-4 AND 6 STRONGLY FAVOR
`INSTITUTION
`A.
`Petitioner Intends to File a Motion to Stay the Parallel
`Litigation (Factor 1)
`Neither party to the litigation has yet requested a stay, but a stay remains
`
`possible. Indeed, Apple’s motion for transfer to the Northern District of California
`
`(“NDCA”) remains pending and, if granted, stay pending institution is likely.
`
`Nevertheless, upon institution of this petition and regardless of the transfer
`
`decision, Petitioner intends to file a motion to stay the parallel litigation.
`
`Accordingly, as noted in the Petition, Factor 1 is at worst neutral (Pet. 94).
`
`B.
`
`The Final Written Decision Deadline Precedes the Median
`Trial Date (Factor 2)
`In June, Director Vidal issued clear guidance on the trial date to use when
`
`considering discretionary denial on the basis of co-pending litigation. Specifically,
`
`“when considering the proximity of the district court’s trial date to the date when
`
`the PTAB final written decision will be due, the PTAB will consider the median
`
`time from filing to disposition of the civil trial for the district in which the parallel
`
`
`
`1
`
`
`
`
`
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
`litigation resides” and cited to statistics.1 Guidance, 3. These statistics show the
`
`“most recent statistics on median time-to-trial for civil actions” in the Western
`
`District of Texas (“WDTX”) as 28.3 months. Here, the complaint against Apple
`
`was filed on September 23, 2021 (APPLE-1009), establishing an expected trial
`
`date of February 2024 based on the WDTX statistics.2 Accordingly, the median
`
`time-to-trial falls after the statutory deadline for the Board’s final written decision
`
`(“FWD”), which is expected to be no later than December 21, 2023.
`
`Patent Owner asks the Board to ignore this guidance and, instead, use the
`
`July 26, 2023 trial date in the scheduling order entered on January 7, 2022.
`
`However, as the Director explained “scheduled trial dates are unreliable and often
`
`change.” Indeed, the district court recently delayed the trial to September 27, 2023
`
`in the amended scheduling order entered on October 20, 2022. APPLE-1028. That
`
`a Markman hearing has not yet been held, and that Apple’s motion to transfer
`
`
`
` Available at https://www.uscourts.gov/statistics/table/na/federal-court-
`
` 1
`
`management-statistics/2022/06/30-2
`
`2 Twenty-eight months from the September 23, 2021 complaint against Apple falls
`
`on January 23, 2024. Thirty percent (i.e., 0.3) of the thirty-one days in January
`
`2024 adds 9.3 days and moves the median time-to-trial to February 1, 2024.
`
`
`
`2
`
`
`
`
`
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
`remains pending, further underscores the uncertainty as to whether and when the
`
`Apple litigation might proceed to trial.
`
`Thus, due to demonstrable unreliability of scheduled trial dates, the Board
`
`should follow the Director’s guidance, i.e., use median time to trial, and find
`
`Factor 2 to favor institution.
`
`However, even if the currently scheduled trial date (September 27, 2023) is
`
`considered, Factor 2 is, at worst, neutral because the Board considers the proximity
`
`of the parallel proceeding to the FWD. When the FWD is due shortly after the
`
`target date—here, at worst, by roughly two and a half months—this factor receives
`
`little weight. Sotera Wireless, Inc. v. Masimo Corp., IPR2020-01019, Paper 12, 15
`
`(2020). Also, “given the minimal, if any, overlap between the issues in the [co-
`
`pending litigation] and this proceeding,” which is the case here as explained in Part
`
`D below, “the time overlap has less significance.” SharkNinja v. iRobot Corp.,
`
`IPR2021-00545, Paper 11, 7 (2021).
`
`C.
`Petitioner’s Diligence Favors Institution (Factor 3)
`The Petition was filed approximately eight months after being served with
`
`the complaint, approximately four months after Jawbone served infringement
`
`contentions, and less than two months after Apple served preliminary invalidity
`
`contentions. With this diligence, the investment in the district court “is not a result
`
`of Petitioner’s delay.” SharkNinja, IPR2021-00545, Paper 11 at 7-8. In fact, the
`
`
`
`3
`
`
`
`
`
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
`deadline to amend pleadings (December 20, 2022) falls before the institution
`
`deadline and significant events (e.g., several months of fact discovery, expert
`
`reports, dispositive motions, a Markman hearing, trial, etc.) will occur in the
`
`district court post-institution. Indeed, a Markman hearing has not yet been held,
`
`Apple’s motion to transfer remains pending, and much of the case remains to be
`
`litigated. Thus, Factor 3 favors institution.
`
`D.
`Petitioner’s Stipulation Favors Institution (Factor 4)
`Patent Owner’s argument that Petitioner has not provided a Sotera
`
`stipulation does not change the weight that should be accorded to Petitioner’s Sand
`
`Revolution stipulation, which resolves doubt as to meaningful overlap of issues
`
`(Pet. 98-99). Sand Revolution II, LLC v. Cont’l Intermodal Grp.-Trucking LLC,
`
`IPR2019-01393, Paper 24 at 11-12 (June 16, 2020).
`
`Specifically, Petitioner’s stipulation prevents overlap because it requires the
`
`grounds addressed in each forum to be mutually exclusive, thereby obviating the
`
`possibility of inconsistent results. With institution, the IPR grounds will not be
`
`considered in the litigation and the same grounds will not be evaluated in both
`
`forums, thereby reducing inefficiency and the risk of inconsistent results.
`
`Moreover, upcoming events in the litigation will dictate a reduction in
`
`overlap between this proceeding and the issues that will be litigated through trial.
`
`In fact, Final Invalidity and Infringement Contentions are not due until December
`
`
`
`4
`
`
`
`
`
`
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`
`13, 2022. APPLE-1028, 1. Also, the court has set deadlines of January 25, 2023
`
`and February 15, 2023 for “meet and confers to discuss significantly narrowing
`
`the number of claims asserted and prior art references at issue to triable limits.”
`
`APPLE-1028, 2. Accordingly, as litigation progresses, the overlap in claim
`
`coverage and/or prior art is almost certain to reduce even more.
`
`E.
`The Compelling Merits Favor Institution (Factor 6)
`The Director’s guidance also confirmed that “the PTAB will not rely on the
`
`Fintiv factors to discretionarily deny institution … where a petition presents
`
`compelling evidence of unpatentability.” Here, as demonstrated in the Petition with
`
`reference to Dr. Kenny’s testimony and additional supporting evidence, the
`
`Petition’s merits are “compelling,” and, as a result, a compelling case of
`
`unpatentability obviates the Board’s need to address the Fintiv factors at all.
`
`Further, although the Patent Owner criticizes Petitioner’s application of the cited
`
`references, the Patent Owner does so solely on the basis of attorney argument that
`
`is unsupported by expert testimony or any other extrinsic evidence.
`
`For the reasons set forth above and in the petition, a holistic view of the
`
`Fintiv factors supports institution.
`
`
`
`
`
`
`
`
`
`5
`
`
`
`Date: October 24, 2022
`
`Respectfully submitted,
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`/Jeremy J. Monaldo/
`W. Karl Renner, Reg. No. 41,265
`Jeremy Monaldo, Reg. No. 58,680
`Richard Wong, Reg. No. 73,259
`Fish & Richardson P.C.
`3200 RBC Plaza, 60 South Sixth Street
`Minneapolis, MN 55402
`T: 202-783-5070
`F: 877-769-7945
`Attorneys for Petitioner
`
`
`
`IPR2022-01084
`U.S. Patent No. 8,321,213
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CFR § 42.6(e), the undersigned certifies that on October 24,
`
`2022, a complete and entire copy of this Petitioner’s Preliminary Reply was
`
`provided via email to the Patent Owner by serving the correspondence email
`
`addresses of record as follows:
`
`Peter Lambrianakos
`Vincent J. Rubino III
`Alfred R. Fabricant
`Enrique W. Iturralde
`Richard Cowell
`FABRICANT LLP
`411 Theodore Fremd Avenue, Suite 206 South
`Rye, New York 10580
`Tel. 212-257-5797
`Fax. 212-257-5796
`
`plambrianakos@fabricantllp.com
`vrubino@fabricantllp.com
`ffabricant@fabricantllp.com
`eiturralde@fabricantllp.com
`rcowell@fabricantllp.com
`ptab@fabricantllp.com
`
`/Crena Pacheco/
`Crena Pacheco
`Fish & Richardson P.C.
`60 South Sixth Street, Suite 3200
`Minneapolis, MN 55402
`(617) 956-5938
`
`